Published in Nat Rev Cancer on June 10, 2010
Surgical outcome of malignant primary bone tumours in elderly and very elderly patients. Int Orthop (2014) 1.97
Incidence, predictive factors, and prognosis of chondrosarcoma in patients with Ollier disease and Maffucci syndrome: an international multicenter study of 161 patients. Oncologist (2011) 1.54
The endocannabinoid system and cancer: therapeutic implication. Br J Pharmacol (2011) 1.46
Ptpn11 deletion in a novel progenitor causes metachondromatosis by inducing hedgehog signalling. Nature (2013) 1.33
Genome-wide analysis of Ollier disease: Is it all in the genes? Orphanet J Rare Dis (2011) 1.24
The imaging of cartilaginous bone tumours. I. Benign lesions. Skeletal Radiol (2012) 1.17
Primary vascular tumors of bone: a spectrum of entities? Int J Clin Exp Pathol (2011) 1.11
Cannabinoids as therapeutic agents in cancer: current status and future implications. Oncotarget (2014) 1.05
Targeting the apoptotic pathway in chondrosarcoma using recombinant human Apo2L/TRAIL (dulanermin), a dual proapoptotic receptor (DR4/DR5) agonist. Mol Cancer Ther (2012) 0.99
FGFR3 Deficiency Causes Multiple Chondroma-like Lesions by Upregulating Hedgehog Signaling. PLoS Genet (2015) 0.99
Mesenchymal stem cell transformation and sarcoma genesis. Clin Sarcoma Res (2013) 0.95
Mutant IDH is sufficient to initiate enchondromatosis in mice. Proc Natl Acad Sci U S A (2015) 0.89
The multiple cellular functions of the oncoprotein Golgi phosphoprotein 3. Oncotarget (2015) 0.89
Therapeutic molecular targets in human chondrosarcoma. Int J Exp Pathol (2010) 0.89
Ageing and the pathogenesis of osteoarthritis. Nat Rev Rheumatol (2016) 0.89
Src kinases in chondrosarcoma chemoresistance and migration: dasatinib sensitises to doxorubicin in TP53 mutant cells. Br J Cancer (2013) 0.88
Putative multifunctional signature of lung metastases in dedifferentiated chondrosarcoma. Sarcoma (2012) 0.87
Targeted disruption of Shp2 in chondrocytes leads to metachondromatosis with multiple cartilaginous protrusions. J Bone Miner Res (2014) 0.87
Loss of β-catenin induces multifocal periosteal chondroma-like masses in mice. Am J Pathol (2012) 0.87
CCL5 promotes VEGF-dependent angiogenesis by down-regulating miR-200b through PI3K/Akt signaling pathway in human chondrosarcoma cells. Oncotarget (2014) 0.86
Loss of pRB and p107 disrupts cartilage development and promotes enchondroma formation. Oncogene (2012) 0.86
Unique mutation portraits and frequent COL2A1 gene alteration in chondrosarcoma. Genome Res (2014) 0.85
Inhibition of mutant IDH1 decreases D-2-HG levels without affecting tumorigenic properties of chondrosarcoma cell lines. Oncotarget (2015) 0.84
BMP and TGFbeta pathways in human central chondrosarcoma: enhanced endoglin and Smad 1 signaling in high grade tumors. BMC Cancer (2012) 0.84
Expression of aromatase and estrogen receptor alpha in chondrosarcoma, but no beneficial effect of inhibiting estrogen signaling both in vitro and in vivo. Clin Sarcoma Res (2011) 0.84
Analysis of PD-L1, T-cell infiltrate and HLA expression in chondrosarcoma indicates potential for response to immunotherapy specifically in the dedifferentiated subtype. Mod Pathol (2016) 0.84
Peripheral chondrosarcoma progression is associated with increased type X collagen and vascularisation. Virchows Arch (2011) 0.83
Involvement of the soluble urokinase receptor in chondrosarcoma cell mobilization. Sarcoma (2010) 0.83
Adiponectin promotes VEGF-A-dependent angiogenesis in human chondrosarcoma through PI3K, Akt, mTOR, and HIF-α pathway. Oncotarget (2015) 0.83
Systemic therapy for selected skull base sarcomas: Chondrosarcoma, chordoma, giant cell tumour and solitary fibrous tumour/hemangiopericytoma. Rep Pract Oncol Radiother (2016) 0.83
Three new chondrosarcoma cell lines: one grade III conventional central chondrosarcoma and two dedifferentiated chondrosarcomas of bone. BMC Cancer (2012) 0.82
Interobserver reliability in the histopathological diagnosis of cartilaginous tumors in patients with multiple osteochondromas. Mod Pathol (2012) 0.82
HSPG-deficient zebrafish uncovers dental aspect of multiple osteochondromas. PLoS One (2012) 0.80
Loss of RUNX3 expression may contribute to poor prognosis in patients with chondrosarcoma. J Mol Histol (2013) 0.80
Comprehensive analysis of published studies involving systemic treatment for chondrosarcoma of bone between 2000 and 2013. Clin Sarcoma Res (2014) 0.80
Molecular Pathogenesis and Diagnostic, Prognostic and Predictive Molecular Markers in Sarcoma. Surg Pathol Clin (2016) 0.78
Preclinical good laboratory practice-compliant safety study to evaluate biodistribution and tumorigenicity of a cartilage advanced therapy medicinal product (ATMP). J Transl Med (2015) 0.78
NFAT restricts osteochondroma formation from entheseal progenitors. JCI Insight (2016) 0.75
The role of mesenchymal stem/progenitor cells in sarcoma: update and dispute. Stem Cell Investig (2014) 0.75
No preclinical rationale for IGF1R directed therapy in chondrosarcoma of bone. BMC Cancer (2016) 0.75
Curcumin binds in silico to anti-cancer drug target enzyme MMP-3 (human stromelysin-1) with affinity comparable to two known inhibitors of the enzyme. Bioinformation (2015) 0.75
Putting the brakes on chondrosarcoma. Oncotarget (2015) 0.75
From an orphan disease to a generalized molecular mechanism: PTPN11 loss-of-function mutations in the pathogenesis of metachondromatosis. Rare Dis (2013) 0.75
Update on hypoxia-inducible factors and hydroxylases in oxygen regulatory pathways: from physiology to therapeutics. Hypoxia (Auckl) (2017) 0.75
rAAV Vectors as Safe and Efficient Tools for the Stable Delivery of Genes to Primary Human Chondrosarcoma Cells In Vitro and In Situ. Sarcoma (2012) 0.75
Response of conventional chondrosarcoma to gemcitabine alone: a case report. Clin Sarcoma Res (2015) 0.75
Primary Cilia and Intraflagellar Transport Proteins in Bone and Cartilage. J Dent Res (2016) 0.75
Molecular basis of differentiation therapy for soft tissue sarcomas. Trends Cancer Res (2016) 0.75
Development and characterization of a human three-dimensional chondrosarcoma culture for in vitro drug testing. PLoS One (2017) 0.75
SHP2 Regulates the Osteogenic Fate of Growth Plate Hypertrophic Chondrocytes. Sci Rep (2017) 0.75
An intracortical chondromyxoid fibroma in the diaphysis of the metatarsal. Skeletal Radiol (2017) 0.75
Quaternary ammonium-melphalan conjugate for anticancer therapy of chondrosarcoma: in vitro and in vivo preclinical studies. Invest New Drugs (2011) 0.75
Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer (2009) 12.92
Developmental regulation of the growth plate. Nature (2003) 11.53
Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med (2009) 8.55
Indian hedgehog signaling regulates proliferation and differentiation of chondrocytes and is essential for bone formation. Genes Dev (1999) 8.43
Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med (2009) 7.23
Hedgehog and Bmp genes are coexpressed at many diverse sites of cell-cell interaction in the mouse embryo. Dev Biol (1995) 5.36
Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study. Lancet Oncol (2009) 3.21
The putative tumour suppressor EXT1 alters the expression of cell-surface heparan sulfate. Nat Genet (1998) 3.14
The clinical approach towards chondrosarcoma. Oncologist (2008) 3.01
Chondrosarcoma of bone: an assessment of outcome. J Bone Joint Surg Am (1999) 2.85
Multiple osteochondromas. Orphanet J Rare Dis (2008) 2.61
BMP and Ihh/PTHrP signaling interact to coordinate chondrocyte proliferation and differentiation. Development (2001) 2.37
A mutant PTH/PTHrP type I receptor in enchondromatosis. Nat Genet (2002) 2.19
Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer. Lancet Oncol (2008) 2.17
The malignant potential of enchondromatosis. J Bone Joint Surg Am (1987) 2.15
Patterns of expression of murine Vgr-1 and BMP-2a RNA suggest that transforming growth factor-beta-like genes coordinately regulate aspects of embryonic development. Genes Dev (1989) 2.10
Ext1-dependent heparan sulfate regulates the range of Ihh signaling during endochondral ossification. Dev Cell (2004) 2.06
Risk factors for survival and local control in chondrosarcoma of bone. J Bone Joint Surg Br (2002) 1.89
Reliability of histopathologic and radiologic grading of cartilaginous neoplasms in long bones. J Bone Joint Surg Am (2007) 1.73
EXT-mutation analysis and loss of heterozygosity in sporadic and hereditary osteochondromas and secondary chondrosarcomas. Am J Hum Genet (1999) 1.70
Assessment of interobserver variability and histologic parameters to improve reliability in classification and grading of central cartilaginous tumors. Am J Surg Pathol (2009) 1.63
Up-regulation of PTHrP and Bcl-2 expression characterizes the progression of osteochondroma towards peripheral chondrosarcoma and is a late event in central chondrosarcoma. Lab Invest (2000) 1.62
Multiple osteochondromas: mutation update and description of the multiple osteochondromas mutation database (MOdb). Hum Mutat (2009) 1.61
Usefulness of radiography in differentiating enchondroma from central grade 1 chondrosarcoma. AJR Am J Roentgenol (1997) 1.61
Regulation of zebrafish skeletogenesis by ext2/dackel and papst1/pinscher. PLoS Genet (2008) 1.59
A mouse model of osteochondromagenesis from clonal inactivation of Ext1 in chondrocytes. Proc Natl Acad Sci U S A (2009) 1.47
Suberoylanilide hydroxamic acid (SAHA) induces apoptosis or autophagy-associated cell death in chondrosarcoma cell lines. Anticancer Res (2008) 1.38
The role of EXT1 in nonhereditary osteochondroma: identification of homozygous deletions. J Natl Cancer Inst (2007) 1.37
Loss of heterozygosity and DNA ploidy point to a diverging genetic mechanism in the origin of peripheral and central chondrosarcoma. Genes Chromosomes Cancer (1999) 1.37
Interaction of Ihh and BMP/Noggin signaling during cartilage differentiation. Dev Biol (1999) 1.37
The clinical management of chondrosarcoma. Curr Treat Options Oncol (2009) 1.34
siRNA-based targeting of antiapoptotic genes can reverse chemoresistance in P-glycoprotein expressing chondrosarcoma cells. Mol Cancer (2009) 1.30
Constitutive hedgehog signaling in chondrosarcoma up-regulates tumor cell proliferation. Am J Pathol (2006) 1.30
Cartilaginous tumors: fast contrast-enhanced MR imaging. Radiology (2000) 1.28
Gli2 and p53 cooperate to regulate IGFBP-3- mediated chondrocyte apoptosis in the progression from benign to malignant cartilage tumors. Cancer Cell (2009) 1.24
Kinome profiling of chondrosarcoma reveals SRC-pathway activity and dasatinib as option for treatment. Cancer Res (2009) 1.22
Hypoxia induces HIF-1alpha and VEGF expression in chondrosarcoma cells and chondrocytes. J Orthop Res (2004) 1.20
PTHR1 mutations associated with Ollier disease result in receptor loss of function. Hum Mol Genet (2008) 1.20
Estrogen signaling is active in cartilaginous tumors: implications for antiestrogen therapy as treatment option of metastasized or irresectable chondrosarcoma. Clin Cancer Res (2005) 1.18
Decreased EXT expression and intracellular accumulation of heparan sulphate proteoglycan in osteochondromas and peripheral chondrosarcomas. J Pathol (2007) 1.17
Absence of IHH and retention of PTHrP signalling in enchondromas and central chondrosarcomas. J Pathol (2005) 1.16
Microvasculature and VEGF expression in cartilaginous tumors. Hum Pathol (2000) 1.08
Molecular analysis of the INK4A/INK4A-ARF gene locus in conventional (central) chondrosarcomas and enchondromas: indication of an important gene for tumour progression. J Pathol (2004) 1.08
Gains, losses, and amplifications of DNA sequences evaluated by comparative genomic hybridization in chondrosarcomas. Am J Pathol (1997) 1.06
CXCR4/SDF1 mediate hypoxia induced chondrosarcoma cell invasion through ERK signaling and increased MMP1 expression. Mol Cancer (2010) 1.05
Chemotherapy and P-glycoprotein expression in chondrosarcoma. J Orthop Res (1998) 1.05
Peripheral chondrosarcoma progression is accompanied by decreased Indian Hedgehog signalling. J Pathol (2006) 1.05
Near-haploidy and subsequent polyploidization characterize the progression of peripheral chondrosarcoma. Am J Pathol (2000) 1.05
Central chondrosarcoma progression is associated with pRb pathway alterations: CDK4 down-regulation and p16 overexpression inhibit cell growth in vitro. J Cell Mol Med (2008) 1.04
The effects of histone deacetylase inhibitors on the induction of differentiation in chondrosarcoma cells. Clin Cancer Res (2007) 1.00
Changes of the p16 gene but not the p53 gene in human chondrosarcoma tissues. Int J Cancer (2000) 1.00
Aberrant heparan sulfate proteoglycan localization, despite normal exostosin, in central chondrosarcoma. Am J Pathol (2009) 1.00
Correlation between clinicopathological features and karyotype in 100 cartilaginous and chordoid tumours. A report from the Chromosomes and Morphology (CHAMP) Collaborative Study Group. J Pathol (2002) 0.98
cDNA expression profiling of chondrosarcomas: Ollier disease resembles solitary tumours and alteration in genes coding for components of energy metabolism occurs with increasing grade. J Pathol (2005) 0.98
siRNA mediated inhibition of MMP-1 reduces invasive potential of a human chondrosarcoma cell line. J Cell Physiol (2005) 0.98
Inhibitory effects of a new bisphosphonate, minodronate, on proliferation and invasion of a variety of malignant bone tumor cells. J Orthop Res (2006) 0.97
2-methoxyestradiol induces apoptosis and cell cycle arrest in human chondrosarcoma cells. J Orthop Res (2007) 0.97
Defective chondrocyte proliferation and differentiation in osteochondromas of MHE patients. Bone (2006) 0.97
Intrinsic radiation resistance in human chondrosarcoma cells. Biochem Biophys Res Commun (2006) 0.96
COX-2 expression in chondrosarcoma: a role for celecoxib treatment? Eur J Cancer (2009) 0.96
Chromosome 9 alterations and trisomy 22 in central chondrosarcoma: a cytogenetic and DNA flow cytometric analysis of chondrosarcoma subtypes. Diagn Mol Pathol (2001) 0.96
Angiogenic cytokines in cartilage tumors. Clin Orthop Relat Res (2002) 0.95
Suppression of chondrosarcoma cells by 15-deoxy-Delta 12,14-prostaglandin J2 is associated with altered expression of Bax/Bcl-xL and p21. Biochem Biophys Res Commun (2005) 0.95
Expression of hypoxia-inducible factor-1alpha and its relationship to tumour angiogenesis and cell proliferation in cartilage tumours. J Bone Joint Surg Br (2008) 0.92
Tyrosine kinase inhibitor SU6668 represses chondrosarcoma growth via antiangiogenesis in vivo. BMC Cancer (2007) 0.92
Multidrug resistance-1 and p-glycoprotein in human chondrosarcoma cell lines: expression correlates with decreased intracellular doxorubicin and in vitro chemoresistance. J Orthop Res (1999) 0.91
EXTra hit for mouse osteochondroma. Proc Natl Acad Sci U S A (2010) 0.91
Correlation of hypoxic signalling to histological grade and outcome in cartilage tumours. Histopathology (2010) 0.89
Differential expression of VEGF-A and angiopoietins in cartilage tumors and regulation by interleukin-1beta. Cancer (2006) 0.89
P-glycoprotein expression in cartilaginous tumors. J Surg Oncol (1997) 0.89
Developmental pathways in musculoskeletal neoplasia: involvement of the Indian Hedgehog-parathyroid hormone-related protein pathway. Pediatr Res (2003) 0.88
Consequences of telomerase inhibition by BIBR1532 on proliferation and chemosensitivity of chondrosarcoma cell lines. Cancer Invest (2008) 0.88
Tenascin-C promotes cell survival by activation of Akt in human chondrosarcoma cell. Cancer Lett (2005) 0.87
Trail-induced apoptosis and interaction with cytotoxic agents in soft tissue sarcoma cell lines. Eur J Cancer (2003) 0.84
Alterations in the regulatory pathway involving p16, pRb and cdk4 in human chondrosarcoma. J Orthop Res (2001) 0.84
Monoclonal antibody to parathyroid hormone-related protein induces differentiation and apoptosis of chondrosarcoma cells. Cancer Lett (2003) 0.84
Alendronate inhibits cell invasion and MMP-2 secretion in human chondrosarcoma cell line. Acta Pharmacol Sin (2007) 0.80
Parathyroid hormone-related protein regulates glioma-associated oncogene transcriptional activation: lessons learned from bone development and cartilage neoplasia. Ann N Y Acad Sci (2008) 0.80
PTEN mutation is rare in chondrosarcoma. Diagn Mol Pathol (2002) 0.79
Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet (2004) 11.37
Detectable clonal mosaicism and its relationship to aging and cancer. Nat Genet (2012) 3.69
Sarcoma derived from cultured mesenchymal stem cells. Stem Cells (2006) 3.40
The clinical approach towards chondrosarcoma. Oncologist (2008) 3.01
Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst (2007) 2.85
Modulating hedgehog signaling can attenuate the severity of osteoarthritis. Nat Med (2009) 2.81
Giant cell tumor of long bone: a Canadian Sarcoma Group study. Clin Orthop Relat Res (2002) 2.60
beta-Catenin stabilization dysregulates mesenchymal cell proliferation, motility, and invasiveness and causes aggressive fibromatosis and hyperplastic cutaneous wounds. Proc Natl Acad Sci U S A (2002) 2.55
Side population cells in human cancers. Cancer Lett (2008) 2.53
Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res (2009) 2.51
Side population cells isolated from mesenchymal neoplasms have tumor initiating potential. Cancer Res (2007) 2.34
Opportunities for improving the therapeutic ratio for patients with sarcoma. Lancet Oncol (2007) 2.23
Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand? Eur J Cancer (2011) 2.23
Genome-wide association study identifies two susceptibility loci for osteosarcoma. Nat Genet (2013) 2.21
Frequent truncating mutations of STAG2 in bladder cancer. Nat Genet (2013) 2.20
A mutant PTH/PTHrP type I receptor in enchondromatosis. Nat Genet (2002) 2.19
Inactive Wnt/beta-catenin pathway in conventional high-grade osteosarcoma. J Pathol (2010) 2.17
Beta-catenin signaling plays a disparate role in different phases of fracture repair: implications for therapy to improve bone healing. PLoS Med (2007) 2.14
Technical considerations in CT-guided radiofrequency thermal ablation of osteoid osteoma: tricks of the trade. AJR Am J Roentgenol (2002) 2.10
A mechanism for gene-environment interaction in the etiology of congenital scoliosis. Cell (2012) 2.08
Complications of elastic stable intramedullary nail fixation of pediatric femoral fractures, and how to avoid them. J Pediatr Orthop (2004) 2.07
Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial. Lancet Oncol (2012) 2.02
Incidence of gastrointestinal stromal tumours is underestimated: results of a nation-wide study. Eur J Cancer (2005) 2.01
Osteosarcoma originates from mesenchymal stem cells in consequence of aneuploidization and genomic loss of Cdkn2. J Pathol (2009) 1.96
Langerhans-cell histiocytosis 'insight into DC biology'. Trends Immunol (2003) 1.85
The indications for and the prognostic significance of amputation as the primary surgical procedure for localized soft tissue sarcoma of the extremity. Ann Surg Oncol (2004) 1.78
DOG1 and CD117 are the antibodies of choice in the diagnosis of gastrointestinal stromal tumours. Histopathology (2010) 1.78
Lymphatics and bone. Hum Pathol (2007) 1.76
Impact of EWS-ETS fusion type on disease progression in Ewing's sarcoma/peripheral primitive neuroectodermal tumor: prospective results from the cooperative Euro-E.W.I.N.G. 99 trial. J Clin Oncol (2010) 1.65
Epigenetic and genetic loss of Hic1 function accentuates the role of p53 in tumorigenesis. Cancer Cell (2004) 1.65
Assessment of interobserver variability and histologic parameters to improve reliability in classification and grading of central cartilaginous tumors. Am J Surg Pathol (2009) 1.63
Glucocorticoid treatment for the prevention of scoliosis in children with Duchenne muscular dystrophy: long-term follow-up. J Bone Joint Surg Am (2013) 1.61
Prognosis of radiation-induced bone sarcoma is similar to primary osteosarcoma. Clin Orthop Relat Res (2006) 1.61
Positive surgical margins in soft tissue sarcoma treated with preoperative radiation: is a postoperative boost necessary? Int J Radiat Oncol Biol Phys (2010) 1.57
The effect of the setting of a positive surgical margin in soft tissue sarcoma. Cancer (2014) 1.57
A nation-wide study comparing sporadic and familial adenomatous polyposis-related desmoid-type fibromatoses. Int J Cancer (2010) 1.56
Growth factors regulate beta-catenin-mediated TCF-dependent transcriptional activation in fibroblasts during the proliferative phase of wound healing. Exp Cell Res (2004) 1.54
Incidence, predictive factors, and prognosis of chondrosarcoma in patients with Ollier disease and Maffucci syndrome: an international multicenter study of 161 patients. Oncologist (2011) 1.54
Tumor-infiltrating macrophages are associated with metastasis suppression in high-grade osteosarcoma: a rationale for treatment with macrophage activating agents. Clin Cancer Res (2011) 1.53
Uncemented tumor endoprostheses at the knee: root causes of failure. Clin Orthop Relat Res (2005) 1.50
Molecular characterization of commonly used cell lines for bone tumor research: a trans-European EuroBoNet effort. Genes Chromosomes Cancer (2010) 1.50
Tumor cell plasticity in Ewing sarcoma, an alternative circulatory system stimulated by hypoxia. Cancer Res (2005) 1.49
Evaluating function and health related quality of life in patients treated for extremity soft tissue sarcoma. Qual Life Res (2006) 1.48
Beta-catenin regulates wound size and mediates the effect of TGF-beta in cutaneous healing. FASEB J (2006) 1.47
Beta-catenin signaling pathway is crucial for bone morphogenetic protein 2 to induce new bone formation. J Biol Chem (2006) 1.46
The clinical approach toward giant cell tumor of bone. Oncologist (2014) 1.46
Identification of a novel, recurrent HEY1-NCOA2 fusion in mesenchymal chondrosarcoma based on a genome-wide screen of exon-level expression data. Genes Chromosomes Cancer (2011) 1.44
The role of epidermal growth factor receptor in chordoma pathogenesis: a potential therapeutic target. J Pathol (2010) 1.43
Cutaneous wound healing: recruiting developmental pathways for regeneration. Cell Mol Life Sci (2012) 1.40
Maternal and neonatal outcomes in pregnancies complicated by bone and soft-tissue tumors. Obstet Gynecol (2004) 1.40
The role of EXT1 in nonhereditary osteochondroma: identification of homozygous deletions. J Natl Cancer Inst (2007) 1.37
Radiation response: an additional unique signature of myxoid liposarcoma. Int J Radiat Oncol Biol Phys (2004) 1.34
EWSR1-CREB1 and EWSR1-ATF1 fusion genes in angiomatoid fibrous histiocytoma. Clin Cancer Res (2007) 1.33
Radiosensitivity translates into excellent local control in extremity myxoid liposarcoma: a comparison with other soft tissue sarcomas. Cancer (2009) 1.33
Diffusion-weighted MRI in the characterization of soft-tissue tumors. J Magn Reson Imaging (2002) 1.33
Functional characterization of osteosarcoma cell lines provides representative models to study the human disease. Lab Invest (2011) 1.32
Somatic loss of maternal chromosome 11 causes parent-of-origin-dependent inheritance in SDHD-linked paraganglioma and phaeochromocytoma families. Oncogene (2004) 1.32
The NFATc2 gene is involved in a novel cloned translocation in a Ewing sarcoma variant that couples its function in immunology to oncology. Clin Cancer Res (2009) 1.31
Soft-tissue tumors: value of static and dynamic gadopentetate dimeglumine-enhanced MR imaging in prediction of malignancy. Radiology (2004) 1.31
Fractures following radiotherapy and limb-salvage surgery for lower extremity soft-tissue sarcomas. A comparison of high-dose and low-dose radiotherapy. J Bone Joint Surg Am (2005) 1.31
Emerging pathways in the development of chondrosarcoma of bone and implications for targeted treatment. Lancet Oncol (2005) 1.30
Constitutive hedgehog signaling in chondrosarcoma up-regulates tumor cell proliferation. Am J Pathol (2006) 1.30
Genome-wide transcriptome analyses reveal p53 inactivation mediated loss of miR-34a expression in malignant peripheral nerve sheath tumours. J Pathol (2010) 1.29
Wnt pathway, an essential role in bone regeneration. J Cell Biochem (2009) 1.29
Langerhans cell histiocytosis: fascinating dynamics of the dendritic cell-macrophage lineage. Immunol Rev (2010) 1.28
Prognostic factors in pulmonary metastasized high-grade osteosarcoma. Pediatr Blood Cancer (2010) 1.27
Human sterile alpha motif domain 9, a novel gene identified as down-regulated in aggressive fibromatosis, is absent in the mouse. BMC Genomics (2007) 1.26
Gli2 and p53 cooperate to regulate IGFBP-3- mediated chondrocyte apoptosis in the progression from benign to malignant cartilage tumors. Cancer Cell (2009) 1.24
Ultrafast mid-IR laser scalpel: protein signals of the fundamental limits to minimally invasive surgery. PLoS One (2010) 1.24
Genome-wide analysis of Ollier disease: Is it all in the genes? Orphanet J Rare Dis (2011) 1.24
Concise review: mesenchymal tumors: when stem cells go mad. Stem Cells (2011) 1.23
NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways. Mol Immunol (2008) 1.23
Osteoid osteoma and osteoblastoma. J Am Acad Orthop Surg (2011) 1.23
Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial. J Clin Oncol (2009) 1.23
Kinome profiling of chondrosarcoma reveals SRC-pathway activity and dasatinib as option for treatment. Cancer Res (2009) 1.22
Giant cell tumor of bone express p63. Mod Pathol (2008) 1.22
Local recurrence of myxofibrosarcoma is associated with increase in tumour grade and cytogenetic aberrations, suggesting a multistep tumour progression model. Mod Pathol (2006) 1.21
Identification of markers to characterize and sort human articular chondrocytes with enhanced in vitro chondrogenic capacity. Arthritis Rheum (2007) 1.20
Diagnosis and prognosis of chondrosarcoma of bone. Expert Rev Mol Diagn (2002) 1.19
Prolonged beta-catenin stabilization and tcf-dependent transcriptional activation in hyperplastic cutaneous wounds. Lab Invest (2005) 1.19
Outcome after pelvic sarcoma resection reconstructed with saddle prosthesis. Clin Orthop Relat Res (2005) 1.19
Estrogen signaling is active in cartilaginous tumors: implications for antiestrogen therapy as treatment option of metastasized or irresectable chondrosarcoma. Clin Cancer Res (2005) 1.18
No genomic aberrations in Langerhans cell histiocytosis as assessed by diverse molecular technologies. Genes Chromosomes Cancer (2009) 1.18
Enchondromatosis (Ollier disease, Maffucci syndrome) is not caused by the PTHR1 mutation p.R150C. Hum Mutat (2004) 1.17
Characterization of the 12q15 MDM2 and 12q13-14 CDK4 amplicons and clinical correlations in osteosarcoma. Genes Chromosomes Cancer (2010) 1.17
Absence of IHH and retention of PTHrP signalling in enchondromas and central chondrosarcomas. J Pathol (2005) 1.16
Desmoplastic fibroma of bone: an immunohistochemical study including beta-catenin expression and mutational analysis for beta-catenin. Hum Pathol (2005) 1.15
Phase 2 study of preoperative image-guided intensity-modulated radiation therapy to reduce wound and combined modality morbidities in lower extremity soft tissue sarcoma. Cancer (2013) 1.14
Surgical downstaging in an open-label phase II trial of denosumab in patients with giant cell tumor of bone. Ann Surg Oncol (2015) 1.14
Cell cycle/apoptosis molecule expression correlates with imatinib response in patients with advanced gastrointestinal stromal tumors. Clin Cancer Res (2009) 1.14
Integrative analysis reveals relationships of genetic and epigenetic alterations in osteosarcoma. PLoS One (2012) 1.13
Lymph node metastasis in soft tissue sarcoma in an extremity. Clin Orthop Relat Res (2004) 1.12
Transactivating mutation of the MYOD1 gene is a frequent event in adult spindle cell rhabdomyosarcoma. J Pathol (2014) 1.12